Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies | Zendy

Oxana V. Galzitskaya | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies

Author(s) -

Oxana V. Galzitskaya

Publication year - 2020

Publication title -

frontiers in molecular neuroscience

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.989

H-Index - 63

ISSN - 1662-5099

DOI - 10.3389/fnmol.2019.00319

Subject(s) - disease , drug , amyloid (mycology) , drug development , neuroscience , medicine , amyloid fibril , drug target , computational biology , drug discovery , chemistry , bioinformatics , amyloid β , pharmacology , biology , pathology

Currently, there is no effective treatment of proteinopathies, as well as their diagnosis in the early stages of the disease until the first clinical symptoms appear. The proposed model of fibrillation of the Aβ peptide and its fragments not only describes molecular rearrangements, but also offers models of processes that occur during the formation of amyloid aggregates. Since this model is also characteristic of other proteins and peptides, a new potential target for drug development in the treatment of Alzheimer’s disease (AD) and other proteinopathies is proposed on the basis of this model. In our opinion, it is oligomers that are promising targets for innovative developments in the treatment of these diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research